Pharmacotherapy or surgery as primary treatment for acromegaly?

Drugs and Aging

Volumn 17, Issue 2, 2000, Pages 81-92

  Ferone, Diego ^a,b   Colao, Annamaria ^b   Van Der Lely, Art Jan ^a   Lamberts, Steven W J ^a,c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; QUINAGOLIDE; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ACROMEGALY; DIARRHEA; FLATULENCE; GASTRITIS; HALLUCINATION; HEADACHE; HOSPITALIZATION; HUMAN; HYPOTENSION; INJECTION PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALABSORPTION; MICROADENOMA; NAUSEA; NIGHTMARE; NOSE CONGESTION; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TUMOR VOLUME; VERTIGO; VOMITING;

EID: 0033859575     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017020-00001     Document Type: Review

References (91)

1. 1. Melmed S. Acromegaly. N Engl J Med 1990; 322: 966-77
2. 2. Lamberts SWJ, van der Lely AJ, de Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism 1995; 44 Suppl. 1: 15-7
3. 3. Ezzat S. Acromegaly. Endocrinol Metab Clin North Am 1997; 26: 703-23
4. 4. Losa M. Pituitary tumors in the elderly. Eur J Endocrinol 1999; 140: 378-80
5. 5. Melmed S, Ho K, Klibanski A, et al. Recent advances in pathogenesis, diagnosis and treatment of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402
6. 6. Colao A, Merola B, Ferone D, et al. Extensive personal experience: acromegaly. J Clin Endocrinol Metab 1997; 82: 2077-81
7. 7. Barkan A. Acromegalic artropathy and sleep apnea in acromegaly. J Endocrinol 1997; 155 Suppl. 1: S41-4
8. 8. Lombardi G, Colao A, Marzullo P, et al. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 1998; 155 Suppl. 1: S33-6
9. 9. Colao A, Cuocolo A, Marzullo P, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17-23
10. 10. Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80: 3223-6
11. 11. Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol 1997; 47: 17-22
12. 12. Colao A, Balzano A, Ferone D, et al. Increased prevalence of colonic polyps and altered lymphocytes subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol 1997; 47: 23-8
13. 13. Orme SM, McNally RJQ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998; 83: 2730-4
14. 14. Melmed S, Ho K, Jackson I, et al. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998; 83: 2646-52
15. 15. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly. J Clin Endocrinol Metab 2000; 85: 526-9
16. 16. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998; 352: 1455-61
17. 17. Lamberts SWJ. Acromegaly and its treatment. J Endocrinol 1998; 155 Suppl. 1: S49-36
18. 18. Bates A, vant'Hoff W, Jones J, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-9
19. 19. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41: 95-102
20. 20. Clayton RN. New developments in the management of acromegaly: should we achieve absolute biochemical cure? J Endocrinol 1998; 155 Suppl. 1: S23-9
21. 21. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000
22. 22. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. J Clin Endocrinol Metab 1995; 80: 2768-75
23. 23. Lamberts SWJ, van der Lely AJ, de Herder WW et al. Octreotide. N Engl J Med 1996; 334: 246-53
24. 24. Shimon I, Melmed S. Management of pituitary tumors. Ann Intern Med 1998; 129: 472-83
25. 25. Yamada S, Aiba T, Takada K, et al. Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Clin Endocrinol 1996; 82: 291-8
26. 26. Ahmed S, Elsheikh M, Page RCL, et al. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 1999; 50: 560-7
27. 27. Clayton RN. How many surgeosn to operate on acromegalic patients? Clin Endocrinol 1999; 50: 557-9
28. 28. Fahlbush R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21: 669-92
29. 29. Abosch A, Tyrrel JB, Lamborn KR, et al. Transsphenoidal microsurgery for growth hormone secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83: 3411-8
30. 30. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-26
31. 31. Freda PU, Wardlaw SL, Post KD. Long-term endocrinologic follow-up after transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89: 353-8
32. 32. Jho HD, Carrau RL, Ko Y. Endoscopic pituitary surgery. In: Wilkins RH, Rengachary SS, editors. Neurosurgical operative atlas. Vol. 5. Park Ridge (IL): American Association of Neurological Surgeons, 1-12
33. 33. Cappabianca P, Alfieri A, de Divitiis E. Endoscopic endonasal transsphenoidal approach to the sella: towards functional endoscopic pituitary surgery (FEPS). Minim Invasive Neurosurg 1998; 41: 66-73
34. 34. Spinas GA, Zapf J, Landolt AM, et al. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh) 1987; 114: 249-56
35. 35. Barkan A, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-8
36. 36. Stevenaert A, Harris AG, Kovacs K, et al. Presurgical octreotide treatment in acromegaly. Metabolism 1992; 41: 51-8
37. 37. Fahlbush R, Giovannelli M, Buchfelder M, et al. Consensus statement in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. J Endocrinol Invest 1993; 16: 449-60
38. 38. Ezzat S, Horvath E, Harris AG, et al. Morphological effects of octreotide on grow th hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79: 113-8
39. 39. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of trassphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999; 84: 3551-5
40. 40. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82: 3308-14
41. 41. Sheaves R, Jenkins P, Blackburn P, et al. Outcome for transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996; 45: 407-13
42. 42. van der Lely AJ, de Herder WW, Lamberts SWJ. The role of radiotherapy in acromegaly. J Clin Endocrinol Metab 1997; 82: 3185-6
43. 43. Wass JAH. Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. J Endocrinol 1997; 155 Suppl. 1: S57-8
44. 44. Eastman RC, Gorden P, Glatstein E, et al. Radiation therapy for acromegaly. Endocrinol Metab Clin North Am 1992; 21: 693-712
45. 45. Thalassinos NC, Tsagarakis S, Ioannides G, et al. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 1998; 138: 160-3
46. 46. Barkan A, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997; 82: 3187-91
47. 47. Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin Endocrinol 1991; 35: 379-97
48. 48. Brada M, Ford D, Aschley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992; 304: 1343-6
49. 49. Lim YJ, Leem W, Kim TS, et al. Four years' experience in the treatment of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 1998; 70 Suppl. 1: 95-109
50. 50. Marcou Y, Plowman PN. Stereotactic radiosurgery for pituitary adenomas. Trends Endocrinol Metab 2000; 11:132-7
51. 51. Jaffe CA, Barkan A. Acromegaly: recognition and treatment. Drugs 1994; 47: 425-45
52. 52. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-23
53. 53. Jackson SNJ, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol 1997; 46: 745-9
54. 54. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study on 64 patients. J Clin Endocrinol Metab 1998; 83: 374-8
55. 55. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998; 139: 516-21
56. 56. Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995; 132: 559-64
57. 57. Ferrari C, Paracchi A, Romano C, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol 1988; 29: 467-76
58. 58. Chiodini PG, Attanasio R, Cozzi R, et al. CV 205-502 in acromegaly. Acta Endocrinol 1993; 128: 389-93
59. 59. Muratori M, Arosio M, Gambino C, et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997; 20: 537-46
60. 60. Bevan JS, Webster J, Burke CK, et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 221-35
61. 61. Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 1997; 155 Suppl. 1: S59-60
62. 62. Lamberts SW, Klijn JG, van Vroonhoven CC, et al. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 1983; 103:446-50
63. 63. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988; 9: 417-36
64. 64. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstrl-5). Endocrinology 1994; 135: 2814-7
65. 65. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5
66. 66. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 1994; 733: 138-46
67. 67. Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analog SMS 201-995. N Engl J Med 1985; 313: 1576-80
68. 68. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-92
69. 69. Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary culture: differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-98
70. 70. Giusti M, Gussoni G, Cuttica CM, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly; six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996; 81: 2089-97
71. 71. Caron P, Morange-Ramos I, Cogne M, et al. Three year follow-up of acromegalic patients treated with intramuscular slow release lanreotide. J Clin Endocrinol Metab 1997; 82: 18-22
72. 72. Razzore P, Colao A, Baldelli R, et al. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol 1999; 51: 159-64
73. 73. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999; 84: 527-32
74. 74. Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 1999; 51: 611-8
75. 75. Colao A, Marzullo P, Ferone D, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999; 22: 40-7
76. 76. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-99
77. 77. Turner HE, Vadivale A, Keenan J, et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol 1999; 51: 275-80
78. 78. Cozzi R, Dallabonzana D, Attanasio R, et al. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 1999; 141: 267-71
79. 79. Lamberts SW, Zweens M, Verschoor L, et al. A comparison among the growth hormone-lowering effect in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, or the combination of both drugs. J Clin Endocrinol Metab 1986; 63: 16-20
80. 80. Wagenaar AH, Harris AG, van der Lely AJ, et al. Dynamic of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol 1991; 125: 637-42
81. 81. Fløgstad AK, Halse J, Grass P, et al. A comparison of of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994; 79: 461-5
82. 2 receptor agonist cabergoline in therapy resistant acromegalic patients. Pituitary 1999; 1: 115-20
83. 83. Chen WY, Chen N, Yun J, et al. In vitro and in vivo studies of antagonistic effect of human growth hormone analogs. J Biol Chem 1994; 269: 15892-7
84. 84. Jaffe CA, Frieberg RD, Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-rcleasing hormone (GHRH) antagonist: direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 1993; 92: 695-701
85. 85. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171-7
86. 86. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-40
87. 87. Lisset CA, Peacey SR, Laing I, et al. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenomas. Clin Endocrinol 1998; 49: 653-7
88. 88. van der Lely A-J, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol 1992; 37: 181-5
89. 89. Turner HE, Adams CBT, Wass JAH. Pituitary tumours in the elderly: a 20-year experience. Eur J Endocrinol 1999; 140: 383-9
90. 90. Clayton RN. Modern management of acromegaly. Q J Med 1993; 86: 285-7
91. 91. Puchner MJA, Knappe UJ, Lüdecke DK. Pituitary surgery in elderly patients with acromegaly. Neurosurgery 1995; 36: 677-84